Veteran immunologist and former Pfizer R&D leader joins Circurna to advance its circular RNA therapeutic platform ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negotiate licensing agreement Altamira Therapeutics Ltd.

HOUSTON and IRVINE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Circurna, (www.circurna.com) a biotechnology company advancing its proprietary ciRNA™ circular RNA platform, and GATC Health, a leading ...

“Circular RNA technology is poised to transform vaccine development as well the treatment of cancers, autoimmune and other diseases. Circurna reflects who we are today and the future we are working ...

Circular RNA (circRNA) is a unique type of non-coding RNA produced by back splicing of mRNA to form the covalent junction without 3’-5’ polarity and poly(A) tail. CircRNA was first discovered about 30 ...

The ELAV protein binds to specific regions of the precursor RNA, namely to so-called reverse complementary sequences (RCMs) in the introns flanking the "backsplice junction" (BSJ) that is crucial for ...

Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery Circular mRNA significantly increasing protein expression vs. linear mRNA Filed provisional patent application, ...

A newly identified class of RNA molecules has been discovered in bacteria living inside the human body. These circular genetic structures, termed obelisks, differ from known viruses and bacteria and ...